Cardiovascular Revascularization Medicine Cardiovascular Revascularization Medicine RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Intracoronary High-Dose Bolus Tirofiban Administration During Complex Coronary Interventions: A United States-based Case Series
The GP IIb/IIIa inhibitors (GPIs) rapidly provide therapeutic levels of platelet aggregation inhibition and serve as adjunct pharmacotherapy to oral P2Y12 inhibitors that exhibit a significant delay in onset of action for patients with Acute Coronary Syndrome (ACS). Intracoronary (IC) administration of the high dose bolus (HDB) tirofiban has not been extensively studied. Compared to intravenous delivery, IC administration can lead to higher local drug concentration and, therefore, provide instantaneous disruption of platelet aggregation in the culprit vessel. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 21, 2017 Category: Cardiology Authors: Charles I. Wilmer Source Type: research

The Impact of Care Management Information Technology Model On Quality Of Care After Coronary Artery Bypass Surgery: “Bridging the Divides”
Reducing readmissions and improving metrics of care are a national priority. Supplementing traditional care with care management may improve outcomes. The Bridges program was an initial evaluation of a care management platform (CareLinkHub), supported by information technology (IT) developed to improve the quality and transition of care from hospital to home after Coronary Artery Bypass Surgery (CABG) and reduce readmissions. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 20, 2017 Category: Cardiology Authors: William S. Weintraub, Daniel Elliott, Zaher Fanari, Jennifer Ostertag-Stretch, Ann Muther, Margaret Lynahan, Roger Kerzner, Tabassum Salam, Herbert Scherrer, Sharon Anderson, Carla A. Russo, Paul Kolm, Terri H. Steinberg Source Type: research

Drug-Coated Balloon Angioplasty for the Management of Recurring Infrapopliteal Disease in Diabetic Patients with Critical Limb Ischemia
To describe the 1-year outcomes of recurring infrapopliteal disease after endovascular revascularization with the Lutonix drug-coated balloons (LDCB) in diabetic patients with Critical Limb Ischemia (CLI), and to benchmark our findings with previously published objective performance goals (OPG) addressing safety and efficacy of new catheter-based therapies for CLI. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 19, 2017 Category: Cardiology Authors: Luis M. Palena, Larry J. Diaz-Sandoval, Efren G òmez Jabalera, Olga Peypoch Perez, Enrico Sultato, Cesare Brigato, Enrico Brocco, Marco Manzi Source Type: research

Assessing the Left Main Stem in the Cardiac Catheterization Laboratory. What is “Significant”? Function, Imaging or both?
Revascularization of significant Left Main Stem (LMS) disease improves clinical outcomes. This can be achieved through either Coronary Artery Bypass Grafting or Percutaneous coronary intervention. Defining a significant stenosis of the LMS can be challenging and debatable, as most data have been derived using angiographic assessment alone, with a threshold of 50% luminal stenosis used as a marker of functional significance. The use of adjunctive technologies like Intravascular Ultrasound and Fractional Flow Reserve has improved our ability to accurately assess the anatomical severity and physiological significance of coron...
Source: Cardiovascular Revascularization Medicine - June 19, 2017 Category: Cardiology Authors: George Kassimis, Giovanni Luigi de Maria, Niket Patel, Tushar Raina, Peter Scott, Rajesh K. Kharbanda, Adrian P. Banning Source Type: research

Association between arterial access site and anticoagulation strategy on major bleeding and mortality: a historical cohort analysis in the Veteran population
Studies have shown reduction in major bleeding with trans-radial intervention (TRI) compared with trans-femoral intervention (TFI), and with use of bivalirudin compared with heparin + glycoprotein IIb/IIIa inhibitors (GPI). We compared major bleeding, mortality and the interaction between arterial access site and the anticoagulant used for PCI in Veterans. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 8, 2017 Category: Cardiology Authors: Jayant Bagai, Bert Little, Subhash Banerjee Source Type: research

Crossing Techniques and Devices in Femoropopliteal Chronic Total Occlusion Intervention
Chronic total occlusions (CTO) are common in patients with symptomatic peripheral arterial disease. Endovascular CTO intervention remains a challenging endeavor for interventionalists, but is being increasingly considered as a plausible alternative to surgical revascularization, even for complex CTO lesions. We review common endovascular techniques using antegrade, retrograde and transcollateral approaches in femoropopliteal CTO intervention. In addition, we review the current literature on the utility, efficacy, and safety of novel crossing and re-entry devices in femoropopliteal CTO interventions. (Source: Cardiovascular...
Source: Cardiovascular Revascularization Medicine - June 7, 2017 Category: Cardiology Authors: Hemal Bhatt, Sean Janzer, Jon C. George Source Type: research

Coronary Bifurcation Model Created using a Novel Directional Heat Injury Catheter
The present study aimed to develop a swine coronary bifurcation model. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 7, 2017 Category: Cardiology Authors: Kenji Nakatsuma, Shin Watanabe, Akihiro Tokushige, Erika Yamamoto, Bingyuan Bao, Hiroki Watanabe, Takeshi Kimura, Naritatsu Saito Source Type: research

Bermuda Triangle: Chronic Kidney Disease, Contrast-Induced Nephropathy, and Atrial Fibrillation
Dear Editor, (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 6, 2017 Category: Cardiology Authors: Levent Cerit Source Type: research

Contrast-induced Acute Kidney Injury in Interventional Cardiology: Emerging Evidence and Unifying Mechanisms of Protection by Remote Ischemic Conditioning
Contrast-induced acute kidney injury (CI-AKI) is a common complication of many diagnostic and therapeutic cardiovascular procedures. It is associated with longer in-hospital stay, more complicated hospitalization course, and higher in-hospital morbidity and mortality. With increasing use of contrast media in various diagnostic and interventional procedures, the prevalence of CI-AKI is expected to rise. Although pre-hydration with intravenous normal saline is recommended in patients with elevated risk of CI-AKI, this approach is often not feasible in many clinical settings. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 5, 2017 Category: Cardiology Authors: Adebayo C. Atanda, Oladipupo Olafiranye Source Type: research

CRT 2017 late-breaking trials
The CRT conference is the platform for interventional cardiology education and news. This year was a great success with many late-breaking trial submissions, a reflection of the success of the meeting in previous years. In this article, we highlight the late-breaking trials presented at this year's conference that will have significant impact on clinical practice. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 1, 2017 Category: Cardiology Authors: M Chadi Alraies, Kyle Buchanan, Ron Waksman Source Type: research

FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices
The 20th annual Cardiovascular Research Technologies (CRT) Conference took place in Washington, DC in February 2017. More than 2000 leading interventional and endovascular specialists attended the four-day international cardiology conference that features cutting-edge research in a unique boutique setting. Given its proximity to the Food and Drug Administration (FDA), a one-and-a-half day FDA Town Hall meeting was created to provide a rare forum for physicians, industry representatives, and governmental figures to discuss current and future technologies within cardiovascular medicine. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 1, 2017 Category: Cardiology Authors: Kyle D Buchanan, M. Chadi Alraies, Ron Waksman Source Type: research

If Only the Doctor Will Let Me Go Home: Same Day Discharge after PCI
Coronary revascularization and home by dinner. Thirty years ago, this would have been dreaming. Admission one day with cardiac catheterization the next was the norm. Several days to consider whether PTCA could be done with surgical backup, then a day or two extra after the PTCA to make sure the sheaths came out of the groin without too much blood loss. The intervention left the coronary unstable without a stent, and the groin was unstable without reliable closure. Reimbursement also encouraged hospitalization while everyone was waiting. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - June 1, 2017 Category: Cardiology Authors: Ian C. Gilchrist Tags: Editorial Source Type: research

Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis
Drug eluting stents reduce the risk of in-stent restenosis but delay healing of the vascular wall. Recent data on late and very late stent thrombosis after drug-eluting stent (DES) implantation have raised concerns about the long-term safety. High lipophilicity of paclitaxel promotes rapid cellular uptake and prolongs its action. This makes paclitaxel a very promising candidate for local drug therapy intended to inhibit the proliferative and migratory processes involved in restenosis following PCI. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - May 31, 2017 Category: Cardiology Authors: Mostafa El-Mokadem, Mohamed El-Ramly, Amr Hassan, Hesham Boshra, Amir AbdelWahab Source Type: research

Here we go Again: Trying to prevent contrast induced nephropathy
… you'd think that by now I'd know'Cause here we go go go go again(Demi Lovato) (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - May 31, 2017 Category: Cardiology Authors: Fabio V. Lima, Luis Gruberg Source Type: research

Comparison between Catheter-Based Delivery of Paclitaxel after bare metal stenting and Drug eluting stents in coronary artery disease patients at high risk for instent restenosis
Drug eluting stents reduce the risk of instent restenosis but delay healing of the vascular wall. Recent data on late and very late stent thrombosis after drug-eluting stent (DES) implantation have raised concerns about the long-term safety. High lipophilicity of paclitaxel promotes rapid cellular uptake and prolongs its action. This makes paclitaxel a very promising candidate for local drug therapy intended to inhibit the proliferative and migratory processes involved in restenosis following PCI. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - May 31, 2017 Category: Cardiology Authors: Mostafa El-Mokadem, Mohamed El-Ramly, Amr Hassan, Hesham Boshra, Amir AbdelWahab Source Type: research